Global Neurology Clinical Trials Market Size study & Forecast, by Phase (Phase I, Phase II, Phase III, Phase IV) by Study Design (Interventional, Observational, Expanded Access), by Indication (Epilepsy, Parkinson's Disease (PD), Huntington's Disease, Str

Global Neurology Clinical Trials Market Size study & Forecast, by Phase (Phase I, Phase II, Phase III, Phase IV) by Study Design (Interventional, Observational, Expanded Access), by Indication (Epilepsy, Parkinson's Disease (PD), Huntington's Disease, Stroke, Traumatic Brain Injury (TBI), Others) and Regional Analysis, 2023-2030

Global Neurology Clinical Trials Market is valued at approximately USD 5.24 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 5.6% over the forecast period 2023-2030. Neurology clinical trials are scientific studies conducted in humans to evaluate the safety and efficacy of new treatments, drugs, devices, or diagnostic procedures for neurological conditions. Neurological conditions are disorders that affect the brain, spinal cord and nerves that control movement, sensation, thinking, and behavior. The Neurology Clinical Trials Market is expanding because of factors such as the rising increasing prevalence of neurological diseases such as Alzheimer’s disease, epilepsy, and stroke and a growing number of clinical trials and research activities.

The growing prevalence of neurological disorders across the globe is fostering market growth. According to a report from Alzheimer Disease International Organization, in the year 2020, globally there were around 55 million people suffering from dementia and this figure is expected to reach 78 million in the year 2030 and 139 million by the year 2050. Furthermore, the rising number of neurological clinical trials activities is further driving the market growth, According to the Alzheimer's Association article ""Alzheimer's Disease Drug Development Pipeline: 2021"", There were 121 drugs in clinical trials to treat Alzheimer's disease, 39 Phase 3 trials are using 29 agents, 73 Phase 2 trials involving 65 agents, and 27 Phase 1 trial including 27 agents. Twelve medicines are now undergoing clinical trials with the goal of improving cognition, and 12 others are meant to treat behavioral and neuropsychiatric problems. As of February 2020, 97 drugs were undergoing studies to modify illness. Along with these, ClinicalTrials.gov reports that as of June 2022, there are 1,755 epilepsy studies in progress. Thus, the rising number of clinical trials activities is driving the market growth. In Addition, increasing funding for neurological studies by public organizations and a significant number of CROs providing neurology clinical research services is creating a lucrative opportunity for the market. However, the high cost of Neurology Clinical Trials stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Neurology Clinical Trials Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the presence of key market players, rising FDA approvals for clinical trials, and the rising prevalence of neurological disorders in the region. Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the rising prevalence of neurological conditions, an increase in the number of collaborations for clinical trials, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:
Supernus Pharmaceuticals, Inc. (Adamas Pharmaceuticals)
AstraZeneca
Novartis AG
Eisai Co., Ltd.
Eli Lilly and Company
Aurora Health Care
AbbVie Inc.
Zydus Group
Athira Pharma, Inc.
Annovis Bio Inc.

Recent Developments in the Market:
 In January 2023, Biogen Inc. entered into an agreement with Alcyone Therapeutics (Alcyone) to develop Alcyone’s ThecaFlex DRx™ System, an implantable medical device for the subcutaneous delivery of antisense oligonucleotide (ASO) therapeutics into the intrathecal space. Through this agreement, Biogen intends to make better use of the ThecaFlex DRxTM System to increase accessibility and the patient treatment experience for a larger population of people with neurological disorders such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS).
 In April 2022, Labcorp, announced the collaboration with Xcell Biosciences. The agreement states that Labcorp and Xcellbio will work together on initiatives to increase the effectiveness and security of cell and gene therapies for conditions such as Parkinson's disease, cancer, and other illnesses.

Global Neurology Clinical Trials Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered – Phase, Study Design, Indication, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Phaseofferings of key players.

The detailed segments and sub-segment of the market are explained below:

By Phase:
Phase I
Phase II
Phase III
Phase IV

By Study Design:
Interventional
Observational
Expanded Access

By Indication:
Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned

Supernus Pharmaceuticals, Inc. (Adamas Pharmaceuticals)
AstraZeneca
Novartis AG
Eisai Co., Ltd.
Eli Lilly and Company
Aurora Health Care
AbbVie Inc.
Zydus Group
Athira Pharma, Inc.
Annovis Bio Inc.